CRISPR BY DESIGN
Live / Registered — Registered (as of 11 Feb 2025)
What this means for you
Registered since 11 Feb 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90981354
- Registration number
- 7689563
- Mark type
- Stylized text
- Filed
- 23 Mar 2021
- Published for opposition
- 21 Jun 2022
- Registered
- 11 Feb 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 042 — Scientific and technological services: Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering
Owner
- Scribe Therapeutics Inc., Alameda, CA, US
- Scribe Therapeutics Inc., Alameda, CA, US
- Scribe Therapeutics Inc., Alameda, CA, US
Prosecution history
- 11 Feb 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 11 Feb 2025 — REGISTERED-PRINCIPAL REGISTER
- 21 Jan 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Jan 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 16 Dec 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 19 Aug 2024 — USE AMENDMENT FILED
- 16 Dec 2024 — DIVISIONAL PROCESSING COMPLETE
- 19 Aug 2024 — DIVISIONAL REQUEST RECEIVED
- 16 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Dec 2024 — SOU EXTENSION 4 GRANTED
- 14 Aug 2024 — SOU EXTENSION 4 FILED
- 22 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 23 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 19 Aug 2024 — TEAS STATEMENT OF USE RECEIVED